RANI Straddle Strategy
RANI (Rani Therapeutics Holdings, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
RANI (Rani Therapeutics Holdings, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $68.6M, a beta of 0.76 versus the broader market, a 52-week range of 0.387-3.87, average daily share volume of 1.0M, a public-listing history dating back to 2021, approximately 105 full-time employees. These structural characteristics shape how RANI stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.76 places RANI roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a straddle on RANI?
A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.
Current RANI snapshot
As of May 15, 2026, spot at $1.10, ATM IV 203.00%, IV rank 42.74%, expected move 58.20%. The straddle on RANI below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this straddle structure on RANI specifically: RANI IV at 203.00% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 58.20% (roughly $0.64 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RANI expiries trade a higher absolute premium for lower per-day decay. Position sizing on RANI should anchor to the underlying notional of $1.10 per share and to the trader's directional view on RANI stock.
RANI straddle setup
The RANI straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RANI near $1.10, the first option leg uses a $1.10 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RANI chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RANI shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.10 | N/A |
| Buy 1 | Put | $1.10 | N/A |
RANI straddle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.
RANI straddle payoff curve
Modeled P&L at expiration across a range of underlying prices for the straddle on RANI. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use straddle on RANI
Straddles on RANI are pure-volatility plays that profit from large moves in either direction; traders typically buy RANI straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
RANI thesis for this straddle
The market-implied 1-standard-deviation range for RANI extends from approximately $0.46 on the downside to $1.74 on the upside. A RANI long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current RANI IV rank near 42.74% is mid-range against its 1-year distribution, so the IV signal is neutral; the straddle thesis on RANI should anchor more to the directional view and the expected-move geometry. As a Healthcare name, RANI options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RANI-specific events.
RANI straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RANI positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RANI alongside the broader basket even when RANI-specific fundamentals are unchanged. Always rebuild the position from current RANI chain quotes before placing a trade.
Frequently asked questions
- What is a straddle on RANI?
- A straddle on RANI is the straddle strategy applied to RANI (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With RANI stock trading near $1.10, the strikes shown on this page are snapped to the nearest listed RANI chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are RANI straddle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the RANI straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 203.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a RANI straddle?
- The breakeven for the RANI straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current RANI market-implied 1-standard-deviation expected move is approximately 58.20%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a straddle on RANI?
- Straddles on RANI are pure-volatility plays that profit from large moves in either direction; traders typically buy RANI straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
- How does current RANI implied volatility affect this straddle?
- RANI ATM IV is at 203.00% with IV rank near 42.74%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.